Article

Clinical and Economic Impact of ‘ROS1-Testing’ Strategy Compared to a ‘No- ROS1-Testing’ Strategy in Advanced NSCLC in Spain

2021-12-01

Abstract excerpt

<h4>Background: </h4> Detection of the ROS1 rearrangement is mandatory in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to allow targeted therapy with specific inhibitors. However, in Spanish clinical practice ROS1 determination is not yet fully widespread. The aim of this study is to determine the clinical and economic impact of sequentially testing ROS1 in addition to EGFR and ALK in Sp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cbeadb04-a8d0-5029-b276-e4c351ff3b13
DOI: 10.21203/rs.3.rs-1103970/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 10 closest

Clinical and Economic Impact of ‘ROS1-Testing’ Strategy Compared to a ‘No- ROS1-Testing’ Strategy in Advanced NSCLC in SpainDOI 10.21203/rs.3.rs-1103970/v1Read

Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective.Semantic proximity Read

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.Semantic proximity Read

Testing for ROS1 in non-small cell lung cancer: a review with recommendationsSemantic proximity Read

Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancerSemantic proximity Read

Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.Semantic proximity Read

Protocol for the economic evaluation of LCS in Ireland: modelling costs, eligibility, and outcomesSemantic proximity Read

Time for Tobacco Elimination: Modelling smoking cessation strategies and lung cancer screening in SingaporeSemantic proximity Read

Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.Semantic proximity Read

Protocol for the economic evaluation of LCS in Ireland: modelling costs, eligibility, and outcomesSemantic proximity Read

The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer.Semantic proximity Read